ClinicalTrials.gg
WithdrawnNCT02900183Updated Dec 18, 2025

Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

A Phase 2 interventional study of ARC-AAT Injection in Alpha-1 Antitrypsin Deficiency, sponsored by Arrowhead Pharmaceuticals. Withdrawn at 4 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Company decision to not initiate trial

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in alpha 1-Antitrypsin Deficiency with a site in Canada — 5 open to participants now, 5 under way, 3 of them phase 3. alpha 1-Antitrypsin Deficiency · Canada.

Enrollment
17th of 17
0 · median 50
Started
2016
with 4 others
Phase 2
6 of 19
none open now
Registered
9th of 19
by date
Lead sponsor
1 of 19
Arrowhead Pharmaceuticals

Among the 19 studies in alpha 1-Antitrypsin Deficiency with a site in Canada, this one is the 17th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2016, is one of 6 in phase 2, and was the 9th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

5 of the 19 studies in alpha 1-Antitrypsin Deficiency with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in alpha 1-Antitrypsin Deficiency with a site in Canada, or all of them as a file.
02

Study summary

Patients with Alpha-1 Antitrypsin Deficiency (AATD) will be enrolled to receive multiple doses of ARC-AAT Injection. All subjects will require a pre-dose biopsy and a biopsy post last dose.

Read the detailed description

This is a multi-center, multi-dose study to evaluate the safety, tolerability and effect on intrahepatic and circulating Alpha-1 Antitrypsin (AAT) levels of ARC-AAT Injection, administered intravenously. Participants who have signed an Institutional Review Board/Ethics Committee (IRB/EC) approved informed consent form and met all of the protocol eligibility criteria will receive multiple intravenous doses (7 total doses administered every 28 days) of ARC-AAT Injection. Patients previously, currently or never receiving AAT augmentation therapy are acceptable for enrollment. All subjects will require a pre-dose biopsy and a post-dose biopsy completed after the last dose or at early termination as applicable. For each participant the duration of the study clinic visits is approximately 49 weeks, from the beginning of the Screening period to the Day 287 End-of-Study (EOS) visit.

The following evaluations will be performed at regular intervals throughout the study: medical history, physical examinations, bee venom allergy blood test, vital sign measurements (blood pressure, temperature, heart rate, respiratory rate), weight, adverse events monitoring, electrocardiograms (ECGs), pregnancy tests (females), concurrent medication evaluation, pulmonary function testing, clinical laboratory tests including hematology, coagulation, chemistry, FibroTest, anti-drug antibodies, drug screens, serum AAT levels, liver biopsy, FibroScan, and urinalysis.

03

Conditions studied

  • Alpha-1 Antitrypsin Deficiency
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-nursing female patients 18-75 years of age, inclusive, at the time of Screening
  • Previous diagnosis of PiZZ genotype Alpha-1 Antitrypsin Deficiency (AATD)
  • Non-smoker (not a daily cigarette smoker) for at least three years with current non-smoking status confirmed by urine cotinine at screening.
  • Highly effective, double barrier (both male and female partners) during the study and for 3 months following the last dose of ARC-AAT Injection
  • Suitable venous access for blood sampling

Exclusion criteria

Exclusion Criteria:

  • Known diagnosis of hepatic fibrosis from a cause other than AATD
  • History of poorly controlled disease, or any history of autoimmune hepatitis
  • (HIV) infection
  • Seropositive for virus (HBV) or virus (HCV)
  • Uncontrolled hypertension
  • History of cardiac rhythm disturbances
  • Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease, (TIA) or cerebrovascular accident (CVA) within 6 months prior to study entry
  • History of within the last 2 years except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer
  • History of major surgery within 1 month of Screening
  • Regular use of alcohol within one month prior to the Screening visit
  • Use of illicit drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to Screening or positive urine drug screen at Screening
  • Use of an agent or device within 30 days prior to dosing or current participation in an investigational study involving a therapeutic intervention
  • Any history/presence of an uncontrolled systemic disease
  • Blood donation (≥500 mL) within 7 days prior to study treatment administration
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    ARC-AAT Injection

    Intravenous administration of ARC-AAT Injection (4 mg/kg or 6 mg/kg) every 28 days for a total of 7 doses

    Drug: ARC-AAT Injection

Interventions

  • DrugARC-AAT Injection

    RNA interference (RNAi)-based, liver-targeted therapeutic

06

What researchers measure

Primary outcomes

  1. Incidence and frequency of adverse events as a measure of safety and tolerability of multiple doses of ARC-AAT Injection

    Time frame: Baseline through Day 287 End-of Study Visit

Secondary outcomes

  1. Change from baseline in circulating serum levels of alpha-1 antitrypsin

    Time frame: Baseline through Day 287 End-of Study Visit

07

Study locations

4 sites
  • Research Site 1
    Toronto, Ontario M5T3A9, Canada
  • Research Site 2
    Dublin, Ireland
  • Research Site 3
    Pavia, 27100, Italy
  • Research Site 4
    Malmö, SE-205 02, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2016
First posted
Sep 14, 2016
StartEst.
Oct 2016
Primary completionActual
Nov 2016
CompletionActual
Nov 2016
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02900183
Responsible party
Sponsor
First posted
Sep 14, 2016
Start date
Oct 2016 (estimated)
Primary completion
Nov 2016
Completion
Nov 2016
Last update
Dec 18, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion